Perception of oral corticosteroids in adult patients with asthma in France.


Journal

The Journal of asthma : official journal of the Association for the Care of Asthma
ISSN: 1532-4303
Titre abrégé: J Asthma
Pays: England
ID NLM: 8106454

Informations de publication

Date de publication:
07 2021
Historique:
pubmed: 15 4 2020
medline: 14 10 2021
entrez: 15 4 2020
Statut: ppublish

Résumé

Oral corticosteroids (OCS) are frequently used as relievers for acute asthma and controllers for severe asthma. However, the relief offered by OCS is counterbalanced by adverse effects. We aimed to describe how patients perceive OCS treatment benefits and risks, and how this could affect their adherence to the treatment. Patients aged ≥18 years with asthma registered with Carenity, an online patient community, were invited to respond to a questionnaire containing 35 closed and 3 open questions to assess their asthma and perceptions of OCS. 268/300 respondents were receiving or had received OCS for asthma (58 for long-term use and 107 for short-term use). The mean age at diagnosis was 21.3 years. 66% had uncontrolled asthma (GINA control score 3 or 4). Although 42% perceived OCS to be efficacious, 46% mentioned adverse effects. Respondents were mostly satisfied with OCS (median = 7.0/10), particularly for efficacy (median = 8.0/10). Respondents reported having strategies to avoid OCS, mainly because of adverse effects. 26% of respondents had previously reduced or stopped OCS; this proportion was 22% for short-term OCS users and 36% for long-term users. 15% of the respondents not receiving long-term OCS would take the treatment without doing anything else if long-term OCS were prescribed; 42% would seek an alternative treatment. OCS for asthma is perceived efficient but associated with adverse effects. Patients seek alternative treatment.

Identifiants

pubmed: 32285714
doi: 10.1080/02770903.2020.1748048
doi:

Substances chimiques

Adrenal Cortex Hormones 0
Anti-Asthmatic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

946-957

Auteurs

Dany Jaffuel (D)

Polyclinique Saint-Privat, Boujan sur Libron, France.
Department of Pneumology, Arnaud de Villeneuve, Regional University Hospital of Montpellier, Montpellier, France.

Caroline Fabry-Vendrand (C)

AstraZeneca, Courbevoie, France.

Elsa Darnal (E)

AstraZeneca, Courbevoie, France.

Ophélie Wilczynski (O)

Carenity, Paris, France.

Emilie Pain (E)

Carenity, Paris, France.

Arnaud Bourdin (A)

CHU Montpellier, PhyMedExp, INSERM, CNRS, Université de Montpellier, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH